PUBLIC CONTRACT · 2025
Aquisição dos Medicamentos TRASTUzumab [600 mg/5 ml Sol inj Fr 5 ml SC], pERTUzumab [60 mg/ml] + TRASTUzumab [60 mg/ml Sol inj Fr 10 ml SC] e Atezolizumab [1200 mg/20 ml Sol inj Fr 20 ml IV] Para a ULSCB
- Contract value
- €106,525.55
- Signed on
- 8 April 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11336119PUBLISHED SUBJECT
Aquisição dos Medicamentos TRASTUzumab [600 mg/5 ml Sol inj Fr 5 ml SC], pERTUzumab [60 mg/ml] + TRASTUzumab [60 mg/ml Sol inj Fr 10 ml SC] e Atezolizumab [1200 mg/20 ml Sol inj Fr 20 ml IV] Para a ULSCB
Parties involved
- Place of performance
- Portugal
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ROCHE FARMACEUTICA QUIMICA, LDA · Tax ID 500233810
Values and timeline
- Contract price
- €106,525.55
- Procedure base price
- €106,525.55
- Total effective price
- Not reported on Portal BASE
- Publication date
- 9 April 2025
- Award date
- 21 March 2025
- Signing date
- 8 April 2025
- Performance period
- 275 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33690000-3 - Medicamentos vários
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7503494
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.